Professor Chi Hin Cho is Distinguished Professor of Pharmacology at Southwest Medical University in China. His current research interests focus on drug development for inflammation and cancers in the gastrointestinal tract. He has served on leading journals in the fields of gastroenterology and pharmacology and as editor of seven books related to inflammation and cancer. He has held numerous senior positions, including the Chair of Pharmacology at Hong Kong University, Chairman and Professor of Pharmacology at the Chinese University of Hong Kong (CUHK), and Research Professor and Associate Director of the School of Biomedical Sciences in the Faculty of Medicine, CUHK. Professionally, he was the President (2006–2010) and Chair of the Presidential Council (2012–2015) of the Gastrointestinal Pharmacology Section of the International Union of Basic and Clinical Pharmacology, and council member of a number of professional bodies in ulcer research and gastrointestinal pharmacology. Dr. Hu obtained his Ph.D. from The Chinese University of Hong Kong, his research interests focus on the development of novel chemotherapeutic agents for the treatment of colorectal cancer, in particular the drug-resistant colorectal cancer. He published more than 20 peer-reviewed papers in this field and served as editorial board member or reviewer for more than 10 international journals in the field of pharmacology and gastroenterology.

• 1. Drug resistence in colorectal cancer: General aspects2. Drug transporters in the development of multidrug resistance in colorectal cancer3. Role pf colorectal cancer stem cells in resistance to apoptosis and treatment in colorectal cancer4. Serrated lesions and stem cells on drug resistance and colon cancer5. Development of novel microRNA-based therapeutics platform for colorectal cancer6. Chemo-sensitizing agents for naturalorigin for colorectal cancer: Pharmacokinetics approaches7. Induction of programmed necrosis by phytochemicals in colorectal cancer8. Predictive biomarkers of drug resistance in colorectal cancer - Recent updates9. Raclb: An emerging therapeutic target for chemoresistance in colorectal cancer10. Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer11. Targeting colorectal cancer via nanodrug delivery systems

Professor Chi Hin Cho is Distinguished Professor of Pharmacology at Southwest Medical University in China. His current research interests focus on drug development for inflammation and cancers in the gastrointestinal tract. He has served on leading journals in the fields of gastroenterology and pharmacology and as editor of seven books related to inflammation and cancer. He has held numerous senior positions, including the Chair of Pharmacology at Hong Kong University, Chairman and Professor of Pharmacology at the Chinese University of Hong Kong (CUHK), and Research Professor and Associate Director of the School of Biomedical Sciences in the Faculty of Medicine, CUHK. Professionally, he was the President (2006–2010) and Chair of the Presidential Council (2012–2015) of the Gastrointestinal Pharmacology Section of the International Union of Basic and Clinical Pharmacology, and council member of a number of professional bodies in ulcer research and gastrointestinal pharmacology. Dr. Hu obtained his Ph.D. from The Chinese University of Hong Kong, his research interests focus on the development of novel chemotherapeutic agents for the treatment of colorectal cancer, in particular the drug-resistant colorectal cancer. He published more than 20 peer-reviewed papers in this field and served as editorial board member or reviewer for more than 10 international journals in the field of pharmacology and gastroenterology.

• 1. Drug resistence in colorectal cancer: General aspects2. Drug transporters in the development of multidrug resistance in colorectal cancer3. Role pf colorectal cancer stem cells in resistance to apoptosis and treatment in colorectal cancer4. Serrated lesions and stem cells on drug resistance and colon cancer5. Development of novel microRNA-based therapeutics platform for colorectal cancer6. Chemo-sensitizing agents for naturalorigin for colorectal cancer: Pharmacokinetics approaches7. Induction of programmed necrosis by phytochemicals in colorectal cancer8. Predictive biomarkers of drug resistance in colorectal cancer - Recent updates9. Raclb: An emerging therapeutic target for chemoresistance in colorectal cancer10. Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer11. Targeting colorectal cancer via nanodrug delivery systems

Professor Chi Hin Cho is Distinguished Professor of Pharmacology at Southwest Medical University in China. His current research interests focus on drug development for inflammation and cancers in the gastrointestinal tract. He has served on leading journals in the fields of gastroenterology and pharmacology and as editor of seven books related to inflammation and cancer. He has held numerous senior positions, including the Chair of Pharmacology at Hong Kong University, Chairman and Professor of Pharmacology at the Chinese University of Hong Kong (CUHK), and Research Professor and Associate Director of the School of Biomedical Sciences in the Faculty of Medicine, CUHK. Professionally, he was the President (2006–2010) and Chair of the Presidential Council (2012–2015) of the Gastrointestinal Pharmacology Section of the International Union of Basic and Clinical Pharmacology, and council member of a number of professional bodies in ulcer research and gastrointestinal pharmacology. Dr. Hu obtained his Ph.D. from The Chinese University of Hong Kong, his research interests focus on the development of novel chemotherapeutic agents for the treatment of colorectal cancer, in particular the drug-resistant colorectal cancer. He published more than 20 peer-reviewed papers in this field and served as editorial board member or reviewer for more than 10 international journals in the field of pharmacology and gastroenterology.

• 1. Drug resistence in colorectal cancer: General aspects2. Drug transporters in the development of multidrug resistance in colorectal cancer3. Role pf colorectal cancer stem cells in resistance to apoptosis and treatment in colorectal cancer4. Serrated lesions and stem cells on drug resistance and colon cancer5. Development of novel microRNA-based therapeutics platform for colorectal cancer6. Chemo-sensitizing agents for naturalorigin for colorectal cancer: Pharmacokinetics approaches7. Induction of programmed necrosis by phytochemicals in colorectal cancer8. Predictive biomarkers of drug resistance in colorectal cancer - Recent updates9. Raclb: An emerging therapeutic target for chemoresistance in colorectal cancer10. Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer11. Targeting colorectal cancer via nanodrug delivery systems